The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Frequency of practice-changing findings identified by comprehensive genomic profiling in non-myeloid hematologic malignancies.
 
Katherine I. Zhou
No Relationships to Disclose
 
Chenyu Lin
No Relationships to Disclose
 
Michelle Green
Employment - N-of-One
Research Funding - Bayer (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from SciMed
 
Bennett Adam Caughey
No Relationships to Disclose
 
Michael Datto
Research Funding - Foundation Medicine (Inst)
Patents, Royalties, Other Intellectual Property - MRT is intellectual property for which I am the 'inventor'. This software is licensed through Duke.
 
John H Strickler
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; GlaxoSmithKline; Inivata; Mereo Biopharma; Natera (Inst); Pfizer; Pionyr; Roche/Genentech (Inst); Seagen; Silverback Therapeutics; Viatris
Research Funding - A*STAR (Inst); Abbvie (Inst); Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Curegenix (Inst); Daiichi Sankyo/Lilly; Erasca, Inc (Inst); Exelixis (Inst); Leap Therapeutics (Inst); Nektar (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Silverback Therapeutics (Inst)
 
Matthew McKinney
Honoraria - Kite/Gilead
Consulting or Advisory Role - BTG; Celgene; Genentech; Kite/Gilead; Molecular Templates; Pharmacyclics; Seagen; Verastem
Speakers' Bureau - Kite/Gilead
Research Funding - BeiGene; Bristol-Myers Squibb; Celgene; Denovo Biopharma; Genentech; Incyte; Molecular Templates; Nordic Nanovector; Pharmacyclics; Unum